Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Poor Glycemic Control Despite Lifestyle Intervention

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.

Also called NCT07920640

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Beijing Supreme Life Pharmaceutical Technology Co., Ltd. (from the registry)
Registry
  • NCT NCT07920640
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07920640. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-20 (anticipated); primary completion 2028-01-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Poor Glycemic Control Despite Lifestyle Intervention
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Fuling Yunhua Granules
Intervention (Drug)
Dihuang Baoyuan Granules
Intervention (Drug)
Fuling Yunhua Granules Matched Placebo
Intervention (Drug)
Dihuang Baoyuan Granules Matched Placebo
Lead sponsor
Beijing Supreme Life Pharmaceutical Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07920640
Content hash
76b9174aa09d867560a8399225c1b845e266027a38cf469e38d7ad00e6ff9ae7